<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05050747</url>
  </required_header>
  <id_info>
    <org_study_id>Elbanna_002</org_study_id>
    <nct_id>NCT05050747</nct_id>
  </id_info>
  <brief_title>Study to Assess the Effect of Intrauterine Adminstration of HCG Versus Endometrial Injury by Pipelle</brief_title>
  <official_title>An Open-label Prospective Controlled Study to Assess the Effect of Intrauterine Adminstration of HCG Versus Endometrial Injury by Pipelle on the Ongoing Pregnancy Rate in Patients With Unexplained Infertility Undergoing Ovulation Induction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wael Elbanna Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National research centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Wael Elbanna Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our study aims to describe the effect of the intrauterine adminstration of HCG versus the&#xD;
      endometrial injury by pipelle on the ongoing pregnancy rate and the biochemical pregnancy&#xD;
      rate in women with unexplained infertility undergoing ovulation induction. Also to describe&#xD;
      the effect on the first trimester miscarriage rate, ectopic pregnancy rate, and multiple&#xD;
      pregnancy.This study is an open-label, prospective, controlled study, multi-center study.&#xD;
&#xD;
      The study participants' relevant medical records will be collected and reviewed after&#xD;
      obtaining informed consent for the participants. The study materials that will be used will&#xD;
      include blood tests, and ultrasound. The study will involve three study arms.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Our study aims to describe the effect of the intrauterine adminstration of HCG versus the&#xD;
      endometrial injury by pipelle on the ongoing pregnancy rate and the biochemical pregnancy&#xD;
      rate in women with unexplained infertility undergoing ovulation induction. Also to describe&#xD;
      the effect on the first trimester miscarriage rate, ectopic pregnancy rate, and multiple&#xD;
      pregnancy.This study is an open-label, prospective, controlled study, multi-center study.&#xD;
&#xD;
      The study participants' relevant medical records will be collected and reviewed after&#xD;
      obtaining informed consent for the participants. The study materials that will be used will&#xD;
      include blood tests, and ultrasound. The study will involve three study arms:&#xD;
&#xD;
      Arm 1: Women with unexplained infertility undergoing ovulation induction following&#xD;
      intrauterine adminstration of HCG on the day of trigger Arm 2: Women with unexplained&#xD;
      infertility undergoing ovulation induction following endometrial injury by pipelle on day 8-9&#xD;
      of the same cycle of ovulation induction Arm 3: Women with unexplained infertility undergoing&#xD;
      ovulation induction following intrauterine adminstration of placebo on the day of trigger&#xD;
&#xD;
      Primary and secondary key measurements will be used in the study.&#xD;
&#xD;
      The primary measures will include:&#xD;
&#xD;
        -  Signs of ongoing pregnancy Presence of intrauterine gestational sac at 12 weeks Presence&#xD;
           of fetal heart pulsation at 12 weeks&#xD;
&#xD;
        -  Two serum β-HCG levels in 48hrs interval to emphasis biochemical pregnancy&#xD;
&#xD;
      The secondary key measures will include:&#xD;
&#xD;
        -  Occurance of abortion in the 1st trimester&#xD;
&#xD;
        -  Appearance of ectopic pregnancy diagnosis by:&#xD;
&#xD;
      Ultrasound Serum β-HCG level Symptoms of pain and bleeding&#xD;
&#xD;
        -  Signs of multiple pregnancy Number of intrauterine gestational sacs Number of fetal&#xD;
           poles Number of fetal heart pulsations&#xD;
&#xD;
        -  Recording the the baseline characteristics of the study participants&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Signs of ongoing pregnancy</measure>
    <time_frame>Till the end of the 1st trimester</time_frame>
    <description>Recording the following for the three arms of the study:&#xD;
Signs of ongoing pregnancy Presence of intrauterine gestational sac at 12 weeks Presence of fetal heart pulsation at 12 weeks&#xD;
Two serum β-HCG levels in 48hrs interval to emphasis biochemical pregnancy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>occurance of abortion or ectopic or multiple pregnancy</measure>
    <time_frame>Till the end of the 1st trimester</time_frame>
    <description>Recording the following for the three arms of the study:&#xD;
Occurance of abortion in the 1st trimester&#xD;
Appearance of ectopic pregnancy diagnosis by:&#xD;
Ultrasound Serum β-HCG level Symptoms of pain and bleeding&#xD;
- Signs of multiple pregnancy Number of intrauterine gestational sacs Number of fetal poles Number of fetal heart pulsations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recording the baseline characteristics of the study participants</measure>
    <time_frame>Before study intervention</time_frame>
    <description>age , height , weight , body mass index</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">402</enrollment>
  <condition>Female Infertility</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <description>Women with unexplained infertility undergoing ovulation induction following intrauterine adminstration of HCG on the day of trigger</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <description>Women with unexplained infertility undergoing ovulation induction following endometrial injury by pipelle on day 8-9 of the same cycle of ovulation induction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <description>Women with unexplained infertility undergoing ovulation induction following intrauterine adminstration of placebo on the day of trigger</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hCG</intervention_name>
    <description>endometrial injury by pipelle on day 8-9 of the same cycle of ovulation induction</description>
    <arm_group_label>Arm 1</arm_group_label>
    <other_name>pipelle</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will include women with unexplained infertility undergoing ovulation&#xD;
        induction following either:&#xD;
&#xD;
          1. Intrauterine adminstration of HCG&#xD;
&#xD;
          2. Endometrial injury by pipelle&#xD;
&#xD;
          3. Intrauterine adminstration of placebo&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Women with primary or secondary infertility due to unexplained infertility&#xD;
&#xD;
          2. The age group of these women was 25-35 years&#xD;
&#xD;
          3. BMI 18.5-29.9 kg/m2&#xD;
&#xD;
          4. Normal hormone profile (FSH &lt;10 mIU/ml on day 2-3 and AMH more than 1)&#xD;
&#xD;
          5. Euthyroid state or controlled thyroid state&#xD;
&#xD;
          6. Bilateral free spill on HSG&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with severe male factor infertility; serum analysis count &lt; 10 million sperms&#xD;
             /mL - sperm motility&lt;15% - 96%&lt;abnormal morphology)&#xD;
&#xD;
          2. Stage III or IV endometriosis&#xD;
&#xD;
          3. Bilateral tubal factor infertility&#xD;
&#xD;
          4. Premature ovarian failure&#xD;
&#xD;
          5. Polycystic ovary syndrome&#xD;
&#xD;
          6. Uterine cavity abnormality&#xD;
&#xD;
          7. Recurrent spontaneous abortion&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Wael Saad Saad El Banna El Banna, MD</last_name>
    <phone>+2 01227760402</phone>
    <email>dr.wael.ss.elbanna@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Manal El-Hinnawi El-Hinnawi, M.Sc.</last_name>
    <phone>01007970546</phone>
    <email>manalelhinnawi@hotmail.com</email>
  </overall_contact_backup>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 13, 2021</study_first_submitted>
  <study_first_submitted_qc>September 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 21, 2021</study_first_posted>
  <last_update_submitted>September 9, 2021</last_update_submitted>
  <last_update_submitted_qc>September 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wael Elbanna Clinic</investigator_affiliation>
    <investigator_full_name>Wael Elbanna</investigator_full_name>
    <investigator_title>Managing director for Wael Elbanna Clinic</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Infertility, Female</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

